Lung cancer trial: can radiation boost targeted drugs for limited metastases?
NCT ID NCT05277844
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial is for people with a specific type of non-small cell lung cancer that has spread to only a few places in the body (oligometastatic) and has a driver mutation like EGFR or ALK. Participants have already been on a targeted therapy pill (TKI) for 2-4 months without their cancer getting worse. Half will continue TKI alone, and the other half will also receive radiation to all known cancer spots. The study aims to see if adding radiation delays cancer progression and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tyrosine kinase inhibitor (TKI) and local consolidative radiation therapy
- What this could lead to
- If successful, this could show that adding radiation to standard TKI therapy helps control cancer spread and delays progression in patients with a limited number of metastases.
- What could go wrong
- This is a phase II trial with only 106 participants, so results are preliminary. Adding radiation may increase side effects without improving survival, and the benefit may not apply to all mutation types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRIVER MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tata Memorial Hospital
RECRUITINGMumbai, Maharashtra, 400012, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?